Ajax Therapeutics

News

Lilly's M&A team strikes again with $2.3bn Ajax takeover

With the ink barely dry on a deal to buy Kelonia, Lilly has signed a $2.3bn deal to acquire Ajax Therapeutics and its JAK2 blood cancer therapy.

News

TIGIT developer iTeos raises $120m, and other financings

Our round-up of notable biotech financings in the last week includes a $120 million direct offering for immunology and inflammation biotech iTeos, and private rounds for L

News

GSK ends dementia alliance with Alector after setbacks

GSK's alliance with Alector to develop two drug candidates for dementia has been terminated in the wake of disappointing clinical trial results.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks